Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India

Chronic myeloid leukemia is a rare malignancy in children, predominantly seen in adolescence, with relatively aggressive disease biology compared with adults. Despite practical constraints like poor treatment adherence and financial unaffordability of second-generation tyrosine kinase inhibitors, as major challenges in management, a 5-year overall survival rate and an event-free survival of 92% and 64%, respectively, were achieved in our study cohort with imatinib as frontline therapy. Dose augmentation of imatinib is a reasonable option in those with a suboptimal response.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 5, 2020 Category: Hematology Authors: Shuvadeep Ganguly, Deepam Pushpam, Agrima Mian, Anita Chopra, Ritu Gupta, Sameer Bakhshi Tags: Original Study Source Type: research